We are searching for a Laboratory Engineer/Scientist for IDL Biotech/AroCell AB. IDL Biotech is a diagnostic company that develops, produces, and markets In Vitro Diagnostic (IVD) tests worldwide for the healthcare sector. IDL Biotech is a subsidiary of AroCell AB. We...
News
Latest news.
See AroCell’s presentation at Stockholm Corporate Finance Life Science Capital Markets Days
On March 9, AroCell, Anders Hultman CEO, presented the latest developments and the future of the company at the Stockholm Corporate Finance Life Science Capital Markets Days at the IVA conference center in Stockholm. Stockholm Corporate Finance arranged the capital...
IDL Biotech is making progress in Africa
IDL Biotech has now received its first order from the company's distributor in Uganda, Medilink Lab & Surgical Ltd. The order refers to TUBEX® TF, IDL Biotech's rapid test for typhoid fever. Uganda will thus be the third country in Africa to which the company...
IDL Biotech signs distributor agreement in Ghana
IDL Biotech continues to expand in Africa. IDL Biotech has signed a distributor agreement with Res Health Consult Ltd covering Ghana. The agreement covers the sale of TUBEX® TF. Since its launch in Africa, the company has focused on finding the right partners for...
Kampen mot cancer samarbete – Så kan nya blodtestet hjälpa läkare avgöra om terapin fungera
IDL Biotech includes additional clinics in its ongoing multicenter study for UBC® Rapid in Sweden.
IDL Biotech currently has a number of ongoing clinical studies both internationally and in Sweden, with the aim of demonstrating the clinical benefit of UBC® Rapid in bladder cancer and having the test included as a complement in the follow-up of patients with bladder...
IDL Biotech signs distributor agreements in Rwanda, South Sudan and Somalia
IDL Biotech continues to expand in Africa. Today, IDL Biotech has signed a distributor agreement with Roi Scientific Ltd covering Rwanda, South Sudan and Somalia. The agreement covers the sale of TUBEX® TF. Since its launch in Africa, the company has focused on...
CEO, Anders Hultman, Commenting on FDA delay due to Covid-19
This weekend the US Food and Drug Administration (FDA) has informed that the impact of the COVID-19 pandemic and the reallocation of staff is leading to an even greater prolonged timeline for reviews of submissions. Anders Hultman, CEO of AroCell, commenting the FDA...
IDL Biotech continues its work on automating the TPS® tumor marker
As previously informed, at the end of 2019, IDL Biotech signed a cooperation agreement with the Chinese company Zecen Biotech, regarding automation of the tumor marker TPS® on all Zecen Biotech's instruments. The development project has proceeded very well and the...
Commenting CEO Transition, interview by Redeye
(In Swedish)